Zobrazeno 1 - 10
of 42
pro vyhledávání: '"J. P. Ferriere"'
Autor:
T. Marquette, C. Klein, V. Comat, R. Mallet, B. De Graeve, V. Houssein, A. Villers, G. Capon, J-C. Bernhard, F. Bladou, J-M. Ferriere, G. Robert
Publikováno v:
European Urology Open Science, Vol 19, Iss , Pp e2164-e2165 (2020)
Externí odkaz:
https://doaj.org/article/fb6e6b0397c5401bb67f440ebc91285a
Autor:
Joseph Gligorov, Praagh-Doreau I Van, Nicole Tubiana-Mathieu, Christelle Jouannaud, M-A Mouret-Reynier, Frédérique Penault-Llorca, Laurence Vanlemmens, B. Nayl, Bettina Weber, F Mayer, H Devaud, Pascale Dubray-Longeras, J. P. Ferriere, Eloise Planchat, Thierry Petit, N. Chalabi, Fabrice Kwiatkowski, J-M Nabholtz, P. Chollet, Catherine Abrial, Olivier Tredan
Publikováno v:
Cancer Research. 71:P3-14
Background: Panitumumab is an antibody targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Consequently, we evaluated the combination of a standard chemotherapy (FEC 100 followed by T) with panitumumab as
Autor:
Hervé Curé, P. Chollet, S. Amat, I. Van Praagh, J. P. Ferriere, M.-A. Mouret–Reynier, Catherine Abrial
Publikováno v:
ONCOLOGIE. 6:187-192
La chimiotherapie neoadjuvante du cancer du sein correspond a l’utilisation d’un traitement cytostatique systemique avant le traitement locoregional (chirurgie et/ou radiotherapie). Initiee dans les annees 1970 pour le traitement des formes local
Autor:
Ph. Chollet, Bétail G, Jacques-Olivier Bay, Chassagne J, Hervé Curé, Sabine Charrier, Y Communal, R. Plagne, G. Portefaix, J. P. Ferriere
Publikováno v:
Bone Marrow Transplantation. 22:845-851
In order to evaluate the mobilization of peripheral blood progenitor cells (PBPC) after an effective induction regimen in breast cancer, we performed a study on 15 breast cancer patients. Between January 1995 and June 1996, these patients received TN
Autor:
P. Chollet, J. P. Ferriere, J.-L. Achard, Jacques Dauplat, Sabine Charrier, Fabrice Kwiatkowski, I. Assier, Hervé Curé
Publikováno v:
American Journal of Clinical Oncology. 21:117-120
This study focused on the correlation between tumor response and patient outcome in 329 breast cancers treated with primary chemotherapy. There were 141 stage IIIB tumors, including 109 inflammatory carcinomas. Other malignancies (34 IIIA, 99 IIB, 55
Autor:
Hervé Curé, J.-L. Achard, Fabrice Kwiatkowski, Sabine Charrier, E. Belembaogo, P. Chollet, J. P. Ferriere, M. Courtadon, M. De Latour, Jacques Dauplat
Publikováno v:
American Journal of Clinical Oncology. 20:219-225
Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpect
Autor:
J.L. Misset, P. Chollet, I. van Praagh, Sabine Charrier, E. Brain, Hervé Curé, J. P. Ferriere, V. Feillel, Jacques Dauplat, M. De Latour
Publikováno v:
European Journal of Cancer. 33:862-866
Neoadjuvant chemotherapy is used to improve patients' survival in locally-advanced and inflammatory breast cancer and to increase conservative surgical procedures in bulky tumours. Pathological complete responses are unusual. The aim of this pilot st
Autor:
Hervé Curé, J.-L. Achard, Jacques Dauplat, M-A Mouret-Reynier, P. Chollet, Frédérique Penault-Llorca, M. De Latour, J. P. Ferriere, S. Amat, G. Le Bouëdec
Publikováno v:
British Journal of Cancer
Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete response after cytotoxic treatment in breast cancer. The purpose of this retrospective study was to assess the outcome of patients fou
Autor:
J.-L. Achard, P. Chollet, Jacques Dauplat, H. Auvray, M. De Latour, J. P. Ferriere, G. Le Bouëdec
Publikováno v:
The Breast. 12:S37-S38
Autor:
Jean-Marc Nabholtz, M.-A. Mouret-Reynier, Bettina Weber, Nicole Tubiana-Mathieu, Laurence Vanlemmens, Frédérique Penault-Llorca, Nassera Chalabi, Hervé Devaud, Christelle Jouannaud, Thierry Petit, Pascale Dubray-Longeras, P. Chollet, Joseph Gligorov, I. Van Praagh-Doreau, Bruno Coudert, Catherine Abrial, Olivier Tredan, B. Nayl, Eloise Planchat, J. P. Ferriere
Publikováno v:
Journal of Clinical Oncology. 29:e11574-e11574
e11574 Background: Panitumumab is an antiboby targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Consequently, we evaluated the combination of a standard chemotherapy (FEC100 followed by T) with panitumu